There have been few studies of angiotensin receptor blocker (ARB) dose in myocardial
infarction (MI) with preserved left ventricular (LV) systolic function. We evaluated the …

Background The mechanisms of antagonism vary between the angiotensin II type 1 receptor
blockers (ARBs): insurmountable antagonism and surmountable antagonism. Recent …

Objective To investigate the association between treatment with an angiotensin receptor
blocker and clinical outcomes in patients with ST segment elevation myocardial infarction …

Background Patients with acute myocardial infarction (AMI) are usually treated with
angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin receptor blockers (ARBs) …

Introduction Recent studies documented the beneficial effect of angiotensin-receptor
blockers (ARBs) on patients (pts) with acute myocardial infarction (AMI) combined with left …

Few studies have investigated whether angiotensin II receptor blocker (ARB) is a practical
alternative to angiotensin-converting enzyme inhibitor (ACEI) for long-term use after acute …

Background: Angiotensin-converting enzyme inhibitors (ACEI) reduce the mortality in the
chronic phase of myocardial infarction (MI), and similar effects of angiotensin receptor …

There is a paucity of evidence on the impact of angiotensin-converting enzyme inhibitors
(ACEi) and angiotensin receptor blockers (ARB) on long-term outcomes in patients with …

This is an evidence report prepared by the University of Connecticut/Hartford Hospital
Evidence-based Practice Center (EPC) concerning the benefits and harms associated with …

Multiple trials over the past several years have examined indications for angiotensin
receptor blockers (ARBs) in the treatment of left ventricular dysfunction, both acutely after …